Multicenter phase Ib/II study of second-line durvalumab and tremelimumab in combination with paclitaxel in patients with biomarker-selected metastatic gastric cancer. - Lee KW; Zang DY; Kim HD; Kim JW; Kim BJ; Kang YK; Ryu MH; Kim HK (British journal of cancer, 2025)